Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To evaluate recurrence-free survival (RFS) in participants with resected pancreatic neuroendocrine tumors (pNETs) randomized to treatment with capecitabine + temozolomide (CAPTEM) compared to observation only. SECONDARY OBJECTIVES: I. To evaluate overall survival (OS) in participants randomized to treatment with CAPTEM compared to observation only. II. To evaluate the safety and tolerability of CAPTEM compared to observation only. BANKING OBJECTIVE: I. To bank specimens for future correlative studies. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14 and temozolomide PO once daily (QD) on days 10-14. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. ARM II: Patients undergo surveillance with no active treatment. After completion of study treatment, patients are followed up every 6 months for 3 years and then annually until 5 years from randomization. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05040360
Study type Interventional
Source Southwest Oncology Group
Contact
Status Not yet recruiting
Phase Phase 2
Start date January 12, 2022
Completion date March 31, 2025

See also
  Status Clinical Trial Phase
Completed NCT00970970 - Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease N/A
Recruiting NCT03891784 - Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors Phase 2
Recruiting NCT03204019 - A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor Phase 2
Completed NCT00804336 - Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors Phase 1
Completed NCT00576680 - RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors Phase 1/Phase 2
Active, not recruiting NCT03074513 - Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Phase 2
Completed NCT03967951 - CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
Completed NCT01024387 - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Phase 2
Not yet recruiting NCT03435770 - Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms N/A
Recruiting NCT02159989 - Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Recruiting NCT04134832 - Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region
Recruiting NCT04505553 - Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer Phase 2
Terminated NCT03947762 - Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.
Active, not recruiting NCT01466036 - Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Phase 2
Completed NCT00942682 - Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors Phase 1
Completed NCT00428220 - A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. N/A
Recruiting NCT03741517 - Biomarker Study of Pancreatic Neuroendocrine Tumours
Recruiting NCT03147768 - Laser Tissue Welding - Distal Pancreatectomy Sealing Study Phase 1
Not yet recruiting NCT03417843 - Safety and Efficacy of an Ablation Catheter for the Treatment of Pancreatic Premalignant Cyctic Lesions. N/A
Completed NCT02355535 - Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 Phase 1